On the latest #BioCenturyThisWeek podcast: A look at China trends from IITs to earlier deals on the eve of BioCentury-BayHelix China Summit Plus: @Roche-Hansoh, @MerckGroup-Silence; @ArrowheadPharma and tau & siRNA expansion and market signals buff.ly/ZI0lzZD

Hansoh Pharma CBO Weiyong Sun describes strategy behind Roche co-development deal in interview with BioCentury buff.ly/pGQmGYJ

Treasury finishing draft COINS Act rule. Final could be influenced by co-development deals like Roche-Hansoh. buff.ly/rAKAfMh

In BioCentury's Deals Report: An agreement with Roche around ADCs could allow Hansoh to opt into global development, expanding its reach around the world; plus Gilead/Vir, Merck KGaA/Silence and more buff.ly/EabQ9JE

A readout in polycythemia vera appears to have triggered an endgame for Silence Therapeutics, which said Monday that Germany-based Merck KGaA would pay $1.3B to acquire it buff.ly/wpPMFNA

An emerging biomarker reads mortality risk through a metabolic lens. Studies of the six-part MVX blood signature show prognostic information beyond established risk measures, hinting at uses in clinical trial design. buff.ly/J2eghwb

On the latest #BioCenturyShow @StephenPHansen speaks with @ArrowheadPharma CEO Chris Anzalone about solving the challenge of delivering #siRNA to extra-hepatic tissues, and how breakthroughs here can enable future growth opportunities for Arrowhead $ARWR buff.ly/DThToy4

In BioCentury's Public Equity Report: After last week's IPOs fizzled somewhat in the aftermarket, City and Iambic posted double-digit gains to restart a winning streak; Aspen and Bambusa lined up in the NASDAQ queue; and more buff.ly/2wt7YMB

Valuing a preclinical biotech at $50B is a bad idea — a Perspective by @StephenPHansen, who argues that, if the rumors are true, Isomorphic Labs would require near perfect clinical execution to justify the valuation buff.ly/nN0TQWz

EMA’s CHMP backs RevMed’s first-in-class pancreatic cancer therapy. Recommendations follow speedy FDA approvals of the RAS(ON) inhibitor and Lilly’s obesity pill Foundayo orforglipron buff.ly/mKZblpR

FDA's rare disease framework initiative marks the start of a journey that it hopes will end with more consistent policies. Success will depend on rebuilding capacity depleted by DOGE cuts. buff.ly/YWUrlBc

Roche turns to Rona for ALK7-siRNA for selective fat loss, as China biotechs fuel a growing RNAi pipeline silencing ALK7 in adipocytes. buff.ly/hrzh5Ao

China’s RNAi pipeline drives dealmaking with the West. Cardiometabolic programs lead the dealmaking as China’s developers push delivery beyond the liver buff.ly/dczJKGs

In BioCentury's Management Tracks: Former Galapagos executives Paul Stoffels and Willemijn Kremer have landed at Armed Cell Therapies and taken rights to CAR T programs that had belonged to their former employer; and more buff.ly/GZalJxz

In BioCentury's Venture Report: OMass' $310M round among biggest in U.K. history for a biotech; OrbiMed's $3B pair of funds; rounds for Souffle and Altay; and more buff.ly/H9UcXW0

First human tau-lowering data from @ArrowheadPharma mark a milestone for brain shuttle–siRNA delivery. But how much tau knockdown delivers benefit without compromising normal neuronal functions remains an open question. $ARWR buff.ly/Gy5YGoj

In BioCentury's Management Tracks: Verastem introduces new CEO as it announces data, funding; plus updates from AL-S and YolTech buff.ly/1h7Rlxq

Fully autonomous labs need human know-how, not just more robots. AstraZeneca, Thermo Fisher, and Sofinnova Partners on capturing bench expertise to enable better experiments and less human intervention buff.ly/iTlNpzR

Beyond patient matching: AI’s role in reshaping trial recruitment. TriNetX, Paradigm, and Tempus tackle feasibility, enrollment workflows, and site activation through different models buff.ly/fWhTvlU

Beyond the medical record: bridging data gaps to uncover disease biology. From physicians’ notes to tissue samples, companies are building a richer picture of disease beyond oncology. buff.ly/oCDrA8f